GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...
New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...
If you’re 60 years of age or older, speak with your healthcare provider or pharmacist about getting vaccinated against RSV. AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is the first ...
As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and ...
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...
New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV ...
The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...
此外,近日GSK公布其RSV疫苗在预防60岁以上老年人3年(3个完整流行季)的保护效力,累积保护效力为63%,然而却呈现显著的下降趋势——从第1年的83%到第2年的56%再到第3年的48%,而Arexvy的初始效力在三款疫苗中已是佼佼者。
A study of long-term care facilities found residents with penicillin allergies were 95% less likely to receive beta-lactam ...
纽约 - 全球生物制药公司辉瑞制药公司(NYSE: ...
The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.
RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.